#China #Shenzhen #Datasea #BCI technology #NeuroVibe

Overview of NeuroVibe Biofeedback System

Datasea Intelligent Technology Ltd., a pioneering technology firm specializing in acoustic solutions and AI, has recently achieved FDA registration and device listing for its NeuroVibe Biofeedback System. This marks a significant milestone as the company transitions from research and development to commercial readiness. The NeuroVibe System, which includes models NV-02 and NV-03, is classified under FDA product code HCC as a Class II 510(k)-exempt biofeedback medical device.

Significance of FDA Registration

The establishment registration and device listing with the FDA do not equate to full FDA approval, yet they signal a crucial progression towards regulatory compliance. Zhixin Liu, CEO of Datasea, emphasized that this registration is a pivotal step in their international commercialization strategy. NeuroVibe harnesses advanced acoustic technology and artificial intelligence to enhance brain health, offering non-invasive solutions tailored for various clinical applications.

Core Technology Features

NeuroVibe integrates several key technological components:
1. Acoustic Stimulation: This feature modulates neural states via targeted acoustic frequencies.
2. Transcranial Vibro-Acoustic Stimulation (tVAS): A non-invasive method designed for neuromodulation.
3. Real-time EEG Acquisition: This component captures and analyzes brainwave signals instantaneously.
4. AI-Assisted Health Management: AI technologies facilitate intelligent analysis and optimization based on individual patient data.

Through these modules, NeuroVibe is equipped to provide real-time biofeedback, enabling comprehensive neurological assessments and targeted wellness applications.

From Hardware to Integrated Solutions

Notably, NeuroVibe transcends conventional EEG devices, aiming to form a cohesive brain health platform. It supports a closed-loop system that integrates acoustic stimulation, signal acquisition, analysis, and feedback mechanisms. Datasea has previously introduced additional acoustic-driven brain-computer interface (BCI) systems. These innovations reflect their commitment to evolving the product ecosystem from hardware-based solutions to software-enhanced platforms.

Focused Commercialization Strategy

Datasea intends to activate early commercialization efforts within the U.S. market by concentrating on compliant applications. Potential areas of utilization for NeuroVibe include:

• - Brain Health Management: Facilitating dynamic tracking of neurological functions.
• - Biofeedback Training: Allowing real-time visualization of physiological signals.
• - Stress Relief: Utilizing vibro-acoustic techniques to influence the autonomic nervous system.
• - Improved Sleep Quality: Implementing closed-loop interventions based on brainwave patterns.
• - Cognitive Function Enhancement: Supporting processes related to attention, memory, and more.

In light of the growing consumer demand for non-invasive health solutions, Datasea's strategy positions NeuroVibe for substantial market opportunities.

Future Outlook and Plans

Datasea remains committed to advancing its technology and enhancing its product offerings while ensuring regulatory compliance and channel development. The company's future endeavors aim to propagate the growth of acoustic AI technology within the brain health sector, enabling global adoption and innovation in the health tech field. As they prepare for a broader market entry, insights acquired from regulatory processes and user feedback will invariably guide the product iteration and validation strategies moving forward.

About Datasea Intelligent Technology Ltd.

Listed on NASDAQ under the ticker DTSS, Datasea is focused on developing cutting-edge solutions in acoustic technology and AI-based digital systems. Their mission is to create impactful products and services that leverage innovative tech to address the evolving needs of the health and wellness sector.